Dihydroartemisinin+ Piperaquine Phosphate Tablet 40+320mg

(Dihydroartemisinin 40mg)

(piperaquine 320mg)

Antimalarial

PHARMACOLOGY

DROA-QUINE is a syiieigistic combination of an aitemisinin derivative and a new

bisquiiioline compound;

It is active against the asexual foiins of plasm odium，schiqoiits aiid gametocytes. Its action

on scliizonts insures a rapid decrease oi pathogenic parasitaemia which leads to a quick

disappearance of clinical signs; its action on gametocytes prevents coitaminatioii.

The absorption of DROA-QUINE after oral intake is rapid and complete; it is

extensively distributed in all tissues.

Half life of DHA is very short (around 2 hours) whereas PPQ is long (around 9 days)

INDICATIONS

DROA-QIJINE® is indicated for the treatment of all kinds of malaria，as long as patients

call take oral medications. It is particularly recommended in the case of multi-i.esistant

Plasmodium lalciparum malaria.

Drug lnteraction:Not clear.

Over Dosage:Not clear

Pregnaney & Lactation and presentation: The pregiiate women with 3 months are prohibited

The later pregnant women nursing mouthers should be taking this medicine under the

physician's OTitictioiis.

ADMINISTOA'nON AND DOSAGE

0ml administration.

Patient should follow doctor's instruction. The recommended dosage is the following

table:

ADVERSE EFFECTS

Few cases of adverse effects have been reported after administration of DROA-QUINE®.

Most of tliein are related to PPQ affecting the digestive tract (nausea，diarrhea，loss of

appetite，etc.) Rare reactions have also been reported (rash, pruritus, etc.)

CONTRAINDICATIONS

As all new drugs, DROA-QUINE® is not recommended during the first trimester of

pregnancy unless vour doctor considers the risk of the disease to be greater.

A new course DROA-QIUNE® should not be taken within four weeks after the first

treatment.

STORAGE

Keep all medicine out of reach of children.

Preserve in tight and lighlproof containers.

Store ill a cool and dry place below 30。C

Validity: Three Years